Advaxis Announces Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial On NSCLC At ASLC 2020 Targeted Therapies Of Lung Cancer Meeting; 'Was 'safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease'